MetLife Investment Management’s Aquestive Therapeutics AQST Stock Holding History

MetLife Investment Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Buy	63,552 +19,145	+43%	+$80.6K	﹤0.01%	2278
2026 Q1	$184K	Sell	44,407 -13,754	-24%	-$55.8K	﹤0.01%	2269
2025 Q4	$376K	Buy	58,161 +9,511	+20%	+$59.3K	﹤0.01%	1931
2025 Q3	$272K	Sell	48,650 -1,374	-3%	-$5.94K	﹤0.01%	2140
2025 Q2	$166K	Buy	50,024 +17,799	+55%	+$51.1K	﹤0.01%	2284
2025 Q1	$93.5K	Sell	32,225 -7,996	-20%	-$24.2K	﹤0.01%	2555
2024 Q4	$143K	Buy	40,221 +4,125	+11%	+$19K	﹤0.01%	2465
2024 Q3	$180K	Buy	36,096 +16,716	+86%	+$65K	﹤0.01%	2337
2024 Q2	$50.4K	Buy	+19,380	New	+$64.7K	﹤0.01%	2758

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

MetLife Investment Management's AQST Position: Q2 2026 in Review

MetLife Investment Management increased its Aquestive Therapeutics (AQST) stake by 43% in Q2 2026, buying an estimated $80.6K and bringing the position to 63,552 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

MetLife Investment Management first reported a position in AQST in Q2 2024 and has held it in 9 quarters since. The position peaked at $376K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

MetLife Investment Management held 63,552 shares of Aquestive Therapeutics worth $264K as of Q2 2026.
MetLife Investment Management bought 19,145 Aquestive Therapeutics shares in Q2 2026, an estimated $80.6K.
Aquestive Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2278 holding.
MetLife Investment Management first reported a position in Aquestive Therapeutics in Q2 2024 and has held it in 9 quarters since.
MetLife Investment Management's Aquestive Therapeutics position peaked at $376K in Q4 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.